The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.

NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...

Intellia Therapeutics, Inc. announced the dosing of the first patient in the global Phase 3 study for NTLA-2002, a CRISPR-based therapy aimed at treating hereditary angioedema (HAE). This ...

(RTTNews) - Intellia Therapeutics, Inc. (NTLA), a gene editing company, announced on Wednesday that the first patient has been dosed in its pivotal Phase 3 HAELO clinical trial of NTLA-2002, an ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) shares acquire momentum first thing. The Cambridge, Mass.-based Intellia, a leading clinical-stage gene editing company focused on revolutionizing medicine ...

NDAQ:NTLA) NTLA ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Intellia Therapeutics, Inc. Shareholders Who Lost Money ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Intellia ...